ES2507091T3 - Nanofiltración de soluciones del factor VII para eliminar virus - Google Patents

Nanofiltración de soluciones del factor VII para eliminar virus Download PDF

Info

Publication number
ES2507091T3
ES2507091T3 ES04804635.3T ES04804635T ES2507091T3 ES 2507091 T3 ES2507091 T3 ES 2507091T3 ES 04804635 T ES04804635 T ES 04804635T ES 2507091 T3 ES2507091 T3 ES 2507091T3
Authority
ES
Spain
Prior art keywords
factor vii
nanofiltration
polypeptides
eliminate viruses
solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04804635.3T
Other languages
English (en)
Spanish (es)
Inventor
Jesper Christensen
Erik Halkjaer
Turid Preuss
Thomas Budde Hansen
Lene Vaedele Madsen Tomoda
Nina Johansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Novo Nordisk Health Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34639198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2507091(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk Health Care AG filed Critical Novo Nordisk Health Care AG
Application granted granted Critical
Publication of ES2507091T3 publication Critical patent/ES2507091T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ES04804635.3T 2003-12-01 2004-12-01 Nanofiltración de soluciones del factor VII para eliminar virus Expired - Lifetime ES2507091T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK200301775 2003-12-01
DKPA200301775 2003-12-01
PCT/EP2004/053206 WO2005054275A2 (en) 2003-12-01 2004-12-01 Nanofiltration of factor vii solutions to remove virus

Publications (1)

Publication Number Publication Date
ES2507091T3 true ES2507091T3 (es) 2014-10-14

Family

ID=34639198

Family Applications (2)

Application Number Title Priority Date Filing Date
ES19186952T Expired - Lifetime ES2926359T3 (es) 2003-12-01 2004-12-01 Filtración de virus de composiciones líquidas del Factor VII
ES04804635.3T Expired - Lifetime ES2507091T3 (es) 2003-12-01 2004-12-01 Nanofiltración de soluciones del factor VII para eliminar virus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES19186952T Expired - Lifetime ES2926359T3 (es) 2003-12-01 2004-12-01 Filtración de virus de composiciones líquidas del Factor VII

Country Status (14)

Country Link
US (8) US20070142625A1 (OSRAM)
EP (3) EP1711513B1 (OSRAM)
JP (3) JP4874806B2 (OSRAM)
KR (1) KR101234170B1 (OSRAM)
CN (3) CN102351953B (OSRAM)
AU (1) AU2004294403A1 (OSRAM)
BR (1) BRPI0416950B8 (OSRAM)
CA (1) CA2545474A1 (OSRAM)
DK (1) DK1711513T3 (OSRAM)
ES (2) ES2926359T3 (OSRAM)
PL (1) PL1711513T3 (OSRAM)
PT (1) PT1711513E (OSRAM)
RU (1) RU2472804C2 (OSRAM)
WO (1) WO2005054275A2 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102351953B (zh) * 2003-12-01 2017-05-10 诺和诺德医疗保健公司 液体因子vii组合物的病毒过滤
DE102005037824A1 (de) * 2005-08-08 2007-02-15 Zlb Behring Gmbh Neuartiges Virusreduktionsverfahren
WO2012090067A1 (en) 2010-12-30 2012-07-05 Lfb Biotechnologies Glycols as pathogen inactivating agents
US10906934B2 (en) 2011-03-25 2021-02-02 Genentech, Inc. Protein purification methods
JP6220392B2 (ja) 2012-06-21 2017-10-25 バクスアルタ ゲーエムベーハー 細胞培養培地のウイルスろ過
TWI641382B (zh) * 2013-01-31 2018-11-21 韓美藥品股份有限公司 於包含因子ｖｉｉ之組成物中使病毒失活之方法
RU2526494C1 (ru) * 2013-03-19 2014-08-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения Российской Федерации" (ГБОУ ВПО ЧелГМА Минздрава России) Способ удаления вируса иммунодефицита человека из спермы мужчины
PL3068417T3 (pl) * 2013-11-15 2024-05-13 F.Hoffmann-La Roche Ag Sposoby inaktywacji wirusów przy użyciu ekologicznych detergentów
CN105435644A (zh) * 2014-09-29 2016-03-30 中国石油化工股份有限公司 一种纳滤膜及其制备方法
CN111511800B (zh) 2017-10-30 2023-11-28 武田药品工业株式会社 灭活脂包膜病毒的环境相容性去污剂
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽
WO2022026451A1 (en) * 2020-07-30 2022-02-03 Amgen Inc. Cell culture media and methods of making and using the same
USD1013170S1 (en) 2020-10-29 2024-01-30 Cilag Gmbh International Surgical instrument assembly

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100501A (en) 1960-12-23 1963-08-13 Crane Co Removable head and seat ball valve construction
JPS6033009B2 (ja) * 1978-12-29 1985-07-31 三菱電機株式会社 マイクロ波発振装置
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
HU218890B (hu) 1991-02-28 2000-12-28 Novo Nordisk A/S Véralvadást gátló módosított VII faktorok, ezeket kódoló polinukleotid molekulák, polinukleotid molekulával transzfektált emlős sejtek és a véralvadást gátló módosított VII faktorokat tartalmazó gyógyászati készítmények, valamint a készítmények ...
DE4142908C2 (de) * 1991-12-24 1994-02-10 Octapharma Ag Glarus Verfahren zur Herstellung eines virusinaktivierten Prothrombinkomplex-Konzentrats (PPSB)
DK38293D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
SE9500724D0 (sv) 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US5677162A (en) 1995-05-01 1997-10-14 New York Blood Center, Inc. Method for activating prothrombin to thrombin
AT406019B (de) * 1995-05-08 2000-01-25 Immuno Ag Verfahren zur herstellung eines arzneimittels enthaltend ein oder mehrere plasmaderivate
EP0860444A1 (en) 1997-02-24 1998-08-26 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) Method for removing viruses from a protein solution
AT405608B (de) * 1997-04-08 1999-10-25 Immuno Ag Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material
AT407159B (de) * 1997-06-13 2001-01-25 Immuno Ag Verfahren zur abreicherung von viralen und molekularen pathogenen aus einem biologischen material
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
ATA159597A (de) * 1997-09-19 2000-09-15 Immuno Ag Präparat zur behandlung von blutgerinnungsstörungen
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US5981254A (en) 1997-10-30 1999-11-09 Haemacure Corporation Process for producing thrombin from plasma
CN1284881A (zh) * 1997-11-05 2001-02-21 吉富制药株式会社 肝素辅助因子ⅱ制剂及其制备方法
FI106465B (fi) 1998-06-10 2001-02-15 Suomen Punainen Risti Veripalv Menetelmä virusturvallisten farmaseuttisten koostumusten valmistamiseksi
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
AU5805500A (en) 1999-07-07 2001-01-30 Maxygen Aps A method for preparing modified polypeptides
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
JP2003521930A (ja) 2000-02-11 2003-07-22 マキシゲン・エイピーエス 第ＶＩＩ因子または第ＶＩＩａ因子様分子
DE60143292D1 (de) 2000-05-03 2010-12-02 Novo Nordisk Healthcare Ag Varianten des menschlichen Koagulationsfaktors VII
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
PL204888B1 (pl) 2000-09-13 2010-02-26 Novo Nordisk Healthcare Ag Wariant polipeptydu czynnika VII, konstrukcja kwasu nukleinowego, rekombinowana komórka gospodarza, zwierzę transgeniczne, sposób wytwarzania wariantu polipeptydu czynnika VII, kompozycja farmaceutyczna i zastosowanie wariantu polipeptydu czynnika VII
EP1325113B1 (en) 2000-10-02 2010-04-21 Novo Nordisk Health Care AG Factor vii glycoforms
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
WO2002077218A1 (en) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
ES2376694T3 (es) 2001-09-27 2012-03-16 Novo Nordisk Health Care Ag Polipã‰ptidos del factor vii de coagulaciã“n humano.
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
AU2002336919A1 (en) 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
WO2003092588A2 (en) 2002-04-30 2003-11-13 Merck & Co., Inc. 4-azasteroid derivatives as androgen receptor modulators
CN1665925A (zh) 2002-04-30 2005-09-07 马克西根控股公司 凝血因子Ⅶ或Ⅶa多肽变体
RS20050051A (sr) 2002-07-23 2007-06-04 Bio-Products & Bio Engineering Ag., Farmaceutski aktivni sastojak preparata i medikamenata koji sadrže trombin ili imaju mogućnost stvaranja trombina
WO2004011023A1 (de) 2002-07-23 2004-02-05 Bio-Products & Bio-Engineering Aktiengesellschaft Thrombingenerierfähige und thrombinhältige pharmazeutische wirkstoffzubereitungen und arzneimittel
ATE505487T1 (de) 2002-09-30 2011-04-15 Bayer Healthcare Llc Fvii- oder fviia-varianten mit erhöhter koagulationswirkung
JP5306597B2 (ja) * 2003-07-01 2013-10-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
CN102351953B (zh) * 2003-12-01 2017-05-10 诺和诺德医疗保健公司 液体因子vii组合物的病毒过滤
FR2901796A1 (fr) 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2904558B1 (fr) 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
FR2910786B1 (fr) 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
FR2947181B1 (fr) 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII

Also Published As

Publication number Publication date
BRPI0416950B1 (pt) 2019-05-28
CN106916802A (zh) 2017-07-04
US20190032026A1 (en) 2019-01-31
BRPI0416950B8 (pt) 2021-05-25
JP4874806B2 (ja) 2012-02-15
US20220064605A1 (en) 2022-03-03
CN106916802B (zh) 2022-03-25
US20170022482A1 (en) 2017-01-26
EP1711513B1 (en) 2014-07-02
WO2005054275A2 (en) 2005-06-16
US20070142625A1 (en) 2007-06-21
CN102351953A (zh) 2012-02-15
DK1711513T3 (da) 2014-09-15
US9102762B2 (en) 2015-08-11
JP5666359B2 (ja) 2015-02-12
US20120115204A1 (en) 2012-05-10
EP3594222A1 (en) 2020-01-15
JP2012021007A (ja) 2012-02-02
BRPI0416950A (pt) 2007-02-13
AU2004294403A1 (en) 2005-06-16
KR101234170B1 (ko) 2013-02-18
KR20070001887A (ko) 2007-01-04
WO2005054275A3 (en) 2005-09-09
EP3594222B1 (en) 2022-08-03
US20080274534A1 (en) 2008-11-06
ES2926359T3 (es) 2022-10-25
EP1711513A2 (en) 2006-10-18
US20200248150A1 (en) 2020-08-06
PT1711513E (pt) 2014-10-02
JP2011173889A (ja) 2011-09-08
CN1890257A (zh) 2007-01-03
BRPI0416950A8 (pt) 2019-01-22
JP2007537994A (ja) 2007-12-27
RU2006118024A (ru) 2008-01-10
CA2545474A1 (en) 2005-06-16
CN102351953B (zh) 2017-05-10
PL1711513T3 (pl) 2014-12-31
RU2472804C2 (ru) 2013-01-20
EP2275432A1 (en) 2011-01-19
US20150299685A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
ES2507091T3 (es) Nanofiltración de soluciones del factor VII para eliminar virus
ES2563305T3 (es) Dispositivo de colágeno y procedimiento de preparación del mismo
ES2504175T3 (es) Composición limpiadora de superficies duras ácida y líquida
ES2600737T3 (es) Absorción de líquidos por materiales estructurales organometálicos
ES2596880T3 (es) Composición para el análisis de glicoproteínas
ECSP045491A (es) Nueva sal formiato de o-desmetil venlafaxina
ES2542853T3 (es) Método para tratar miastenia grave
ES2092228T3 (es) Nueva membrana de fibras huecas de alto flujo.
BRPI0516682A (pt) meio de filtração e processo para filtrar matéria particulada
CR8997A (es) Produccion de polipeptidos
ES2162517T3 (es) Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
JP2008500279A5 (OSRAM)
AR038648A1 (es) Hormona paratiroidea en forma cristalina y proceso para purificar la hormona paratiroidea y obtener dicha forma cristalina
CL2017002233A1 (es) Un factor de coagulación (fvii o fviia) modificado con tres péptidos carboxi terminal de gonadotropina coriónica unidos al carboxi terminal de fvii o fviia; polinucleótido que lo codifica; composición farmacéutica que lo comprende; uso de fvii o fviia modificado para el tratamiento de coagulación de la sangre o un trastorno de coagulación; método para extender la vía media biológica de un factor de coagulación; método para producir dicho fvii o fviia.
AR044748A1 (es) Cartucho y metodo para la preparacion de bebidas
RU2008136191A (ru) Лечение рака мочевого пузыря с использованием ео9 и пропиленгликоля
ES2526912T3 (es) Composición farmacéutica que contiene neurotoxina botulínica A2
ES2651027T3 (es) Retirada de azufre usando absorbente de carbonato ferroso
PE20030298A1 (es) Filtros de agua y procesos para la utilizacion de los mismos
BRPI0400375B8 (pt) processo para remover vírus em soluções de fibrinogênio para aplicação terapêutica
ES2507094T3 (es) Proteína específica del timo
ES2562347T3 (es) Dispositivo de proyección de chorros de agua mediante una placa perforada curvada
ES2632933T3 (es) Composición de limpieza de enzimas y método de uso
ES2657048T3 (es) Composición para la utilización en el tratamiento local de afecciones bucofaríngeas que comprende ibuprofeno o ketoprofeno
ES2481450T3 (es) Proteasas específicas de ubiquitina responsables de la estabilidad de mcl 1 y su utilización